Report error Found 99 of ic50 data for complexid = 167
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.10nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.20nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.40nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.60nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.20nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.20nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.40nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.70nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.90nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 5.20nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 5.70nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 6.5nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 8nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 16.9nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 30nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 60nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 72nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 90nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 96nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 99nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 110nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 110nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 110nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 110nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 120nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 120nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 120nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 130nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 150nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 150nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 150nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 170nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 180nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 180nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 180nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 190nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 190nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 220nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 220nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 250nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 250nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Human)
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 260nMAssay Description:Assays were performed in white, flat-bottom, 384-well ProxiPlates (Perkin Elmer). The final assay volume was 10 μL prepared from additions of Hi...More data for this Ligand-Target Pair
